Evidence map›Paper›PMID 31543819›Full record

ArticleFrontiers in pharmacology2019

Characterization of the

Yuriy N Davidyuk, Emmanuel Kabwe, Venera G Shakirova, Ekaterina V Martynova, Ruzilya K Ismagilova, Ilsiyar M Khaertynova, Svetlana F Khaiboullina, Albert A Rizvanov, Sergey P Morzunov

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Prevalence of thePathogens (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Yuriy N DavidyukOpenLab Gene and Cell Technologies, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.
Emmanuel KabweOpenLab Gene and Cell Technologies, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.
Venera G ShakirovaDepartment of Infectious Diseases, Kazan State Medical Academy, Kazan, Russia.
Ekaterina V MartynovaOpenLab Gene and Cell Technologies, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.
Ruzilya K IsmagilovaResearch Laboratory "Omics technology", Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.
Ilsiyar M KhaertynovaDepartment of Infectious Diseases, Kazan State Medical Academy, Kazan, Russia.
Svetlana F KhaiboullinaOpenLab Gene and Cell Technologies, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.
Albert A RizvanovOpenLab Gene and Cell Technologies, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.
Sergey P MorzunovDepartment of Pathology, University of Nevada, Reno, NV, United States.
Kazan Federal University · RUKazan State Medical Academy · RUUniversity of Nevada, Reno · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over 1,000 cases of hemorrhagic fever with renal syndrome (HFRS) were recorded in the Republic of Tatarstan (RT) in 2015. HFRS is a zoonotic disease caused by several different Old World hantaviruses. In RT,

Indexed as

HFRSPuumala orthohantavirusPUUVRepublic of TatarstanRNA

Identifiers

PMID31543819
PMCPMC6739438
OpenAlexW2964664560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.